{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:52:22Z","timestamp":1771512742055,"version":"3.50.1"},"reference-count":18,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skin Appendage Disord"],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>Ibrutinib is an oral covalent inhibitor of the Bruton\u2019s tyrosine kinase pathway and is approved for the treatment of B-cell malignancies including chronic lymphocytic leukaemia, mantle cell lymphoma, and Waldenstr\u00f6m\u2019s macroglobulinaemia. It is generally a drug of choice for high-risk patients with indolent lymphomas. The safety profile of ibrutinib appears to be tolerable, with well-known side effects such as infections and haematologic complications. Additionally, dermatological adverse reactions with ibrutinib therapy have been reported to encompass maculopapular rash and hair\/nail abnormalities. Here, we present a case of ibrutinib-induced paronychia and periungual granulation in a 40-year-old woman. To the best of our knowledge, this is the third description of ibrutinib-induced paronychia and periungual granulation.<\/jats:p>","DOI":"10.1159\/000502986","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T21:00:32Z","timestamp":1570568432000},"page":"32-36","source":"Crossref","is-referenced-by-count":10,"title":["Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report"],"prefix":"10.1159","volume":"6","author":[{"given":"Ahu","family":"Yorulmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basak","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-54490-3_17"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.164103"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.874"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7603\/s40681-015-0019-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0384-3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000073100"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2747"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212516"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.032"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.02.001"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000497356"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40800-017-0060-1"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.0225"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.10.009"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20163817"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1986.tb00439.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.3872"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001651"}],"container-title":["Skin Appendage Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/502986","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/502986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:56:56Z","timestamp":1745423816000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000502986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,21]]},"published-print":{"date-parts":[[2020,1,21]]}},"URL":"https:\/\/doi.org\/10.1159\/000502986","archive":["Portico"],"relation":{},"ISSN":["2296-9195","2296-9160"],"issn-type":[{"value":"2296-9195","type":"print"},{"value":"2296-9160","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,8]]}}}